Prestige Consumer Healthcare/$PBH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prestige Consumer Healthcare
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Ticker
$PBH
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
600
ISIN
US74112D1019
Website
PBH Metrics
BasicAdvanced
$3.8B
18.07
$4.29
0.45
-
Price and volume
Market cap
$3.8B
Beta
0.45
52-week high
$90.04
52-week low
$64.94
Average daily volume
360K
Financial strength
Current ratio
4.205
Quick ratio
2.667
Long term debt to equity
56.445
Total debt to equity
56.911
Interest coverage (TTM)
7.33%
Profitability
EBITDA (TTM)
379.414
Gross margin (TTM)
56.54%
Net profit margin (TTM)
18.86%
Operating margin (TTM)
30.70%
Effective tax rate (TTM)
24.49%
Revenue per employee (TTM)
$1,900,000
Management effectiveness
Return on assets (TTM)
6.50%
Return on equity (TTM)
12.30%
Valuation
Price to earnings (TTM)
18.075
Price to revenue (TTM)
3.387
Price to book
2.09
Price to tangible book (TTM)
-3.89
Price to free cash flow (TTM)
15.839
Free cash flow yield (TTM)
6.31%
Free cash flow per share (TTM)
489.55%
Growth
Revenue change (TTM)
1.10%
Earnings per share change (TTM)
2.88%
3-year revenue growth (CAGR)
1.54%
10-year revenue growth (CAGR)
4.76%
3-year earnings per share growth (CAGR)
2.02%
10-year earnings per share growth (CAGR)
11.15%
What the Analysts think about PBH
Analyst ratings (Buy, Hold, Sell) for Prestige Consumer Healthcare stock.
Bulls say / Bears say
Analysts have recently upgraded Prestige Consumer Healthcare's stock rating to 'Buy', indicating confidence in the company's future performance. (Defense World)
The company has demonstrated strong financial health, with a net income of $205.3 million in 2022, reflecting robust profitability. (Wikipedia)
Prestige Consumer Healthcare's diversified portfolio of well-known over-the-counter healthcare brands positions it favorably in the market. (Wikipedia)
Insider selling activity, such as the sale of 1,678 shares by SVP Mary Beth Fritz, may raise concerns about internal confidence in the company's stock. (American Banking and Market News)
The company's P/S ratio of 3.2x is higher than the industry median, suggesting potential overvaluation. (Simply Wall St News)
Recent downgrades by analysts, such as StockNews.com lowering the rating to 'Hold', may indicate concerns about future performance. (American Banking and Market News)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
PBH Financial Performance
Revenues and expenses
PBH Earnings Performance
Company profitability
PBH News
AllArticlesVideos
Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination
GlobeNewsWire·3 weeks ago
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
GlobeNewsWire·1 month ago
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prestige Consumer Healthcare stock?
Prestige Consumer Healthcare (PBH) has a market cap of $3.8B as of July 11, 2025.
What is the P/E ratio for Prestige Consumer Healthcare stock?
The price to earnings (P/E) ratio for Prestige Consumer Healthcare (PBH) stock is 18.07 as of July 11, 2025.
Does Prestige Consumer Healthcare stock pay dividends?
No, Prestige Consumer Healthcare (PBH) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Prestige Consumer Healthcare dividend payment date?
Prestige Consumer Healthcare (PBH) stock does not pay dividends to its shareholders.
What is the beta indicator for Prestige Consumer Healthcare?
Prestige Consumer Healthcare (PBH) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.